Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Importance of the integrated test in the Down's syndrome screening algorithm

D. Springer, J. Loucky, P. Tesner, D. Cutka, D. Stejskal, V. Gregor, T. Zima,

. 2018 ; 25 (3) : 114-118. [pub] 20180325

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19035332

OBJECTIVE: In the Czech Republic, over 97% of all pregnant women undergo some type of antenatal screening for Down's syndrome. In about 95% of cases with a confirmed fetal chromosomal abnormality, the pregnancy is terminated. The most commonly used test is the first trimester combined test. We investigated the impact of implementing an integrated sequential test to improve the detection of Down's syndrome pregnancies. METHODS: Data on the incidence of congenital defects, number of births, and affected pregnancies terminated are recorded in the National Registry of Congenital Anomalies. Anonymous data on cases of Down's syndrome diagnosed antenatally or postnatally between 2010 and 2015 in one of the large antenatal care centers were analyzed. RESULTS: There were 600 diagnoses of Down's syndrome (5.7 per 1000 births), 90% of which were made antenatally. Of antenatally detected cases, 80% were indicated for diagnostic procedure by multimarker screening results. In the multimarker screen positive group, 75% cases were first trimester positive and 25% second trimester positive (most of these had positive integrated test results). Among Down's syndrome cases indicated for antenatal diagnosis by multimarker screening results 6.25% (n = 26) were first trimester negative, and became positive after integration with the second trimester screening results. CONCLUSIONS: Results from five major Czech antenatal centers confirm that an integrated sequential test would detect 80-85% of Down's syndrome fetuses in the first trimester and at least an extra 5-10% of Down's syndrome pregnancies in the second trimester of pregnancy. These are important data that should be considered in implementing the national antenatal screening program.

000      
00000naa a2200000 a 4500
001      
bmc19035332
003      
CZ-PrNML
005      
20191126090437.0
007      
ta
008      
191007s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1177/0969141317752533 $2 doi
035    __
$a (PubMed)29575979
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Springer, Drahomira $u 1 First Faculty of Medicine, Department of Medical Biochemistry and Laboratory Diagnostics, Charles University, Prague, Czech Republic.
245    10
$a Importance of the integrated test in the Down's syndrome screening algorithm / $c D. Springer, J. Loucky, P. Tesner, D. Cutka, D. Stejskal, V. Gregor, T. Zima,
520    9_
$a OBJECTIVE: In the Czech Republic, over 97% of all pregnant women undergo some type of antenatal screening for Down's syndrome. In about 95% of cases with a confirmed fetal chromosomal abnormality, the pregnancy is terminated. The most commonly used test is the first trimester combined test. We investigated the impact of implementing an integrated sequential test to improve the detection of Down's syndrome pregnancies. METHODS: Data on the incidence of congenital defects, number of births, and affected pregnancies terminated are recorded in the National Registry of Congenital Anomalies. Anonymous data on cases of Down's syndrome diagnosed antenatally or postnatally between 2010 and 2015 in one of the large antenatal care centers were analyzed. RESULTS: There were 600 diagnoses of Down's syndrome (5.7 per 1000 births), 90% of which were made antenatally. Of antenatally detected cases, 80% were indicated for diagnostic procedure by multimarker screening results. In the multimarker screen positive group, 75% cases were first trimester positive and 25% second trimester positive (most of these had positive integrated test results). Among Down's syndrome cases indicated for antenatal diagnosis by multimarker screening results 6.25% (n = 26) were first trimester negative, and became positive after integration with the second trimester screening results. CONCLUSIONS: Results from five major Czech antenatal centers confirm that an integrated sequential test would detect 80-85% of Down's syndrome fetuses in the first trimester and at least an extra 5-10% of Down's syndrome pregnancies in the second trimester of pregnancy. These are important data that should be considered in implementing the national antenatal screening program.
650    _2
$a dospělí $7 D000328
650    _2
$a algoritmy $7 D000465
650    _2
$a bezbuněčný systém $7 D002474
650    _2
$a lidský choriogonadotropin, beta podjednotka $x krev $7 D018997
650    _2
$a rozhodování $7 D003657
650    _2
$a Downův syndrom $x diagnóza $7 D004314
650    _2
$a falešně pozitivní reakce $7 D005189
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a plošný screening $x metody $7 D008403
650    _2
$a věk matky $7 D008423
650    _2
$a měření nuchální translucence $7 D048208
650    _2
$a peptidové fragmenty $x krev $7 D010446
650    _2
$a těhotenství $7 D011247
650    _2
$a první trimestr těhotenství $7 D011261
650    _2
$a druhý trimestr těhotenství $7 D011262
650    _2
$a těhotenský plazmatický protein A $x metabolismus $7 D011266
650    _2
$a prenatální diagnóza $x metody $7 D011296
650    _2
$a registrace $7 D012042
650    _2
$a ultrasonografie prenatální $7 D016216
651    _2
$a Česká republika $7 D018153
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Loucky, Jaroslav $u 2 Prediko Centre for Foetal Medicine, Zlin, Czech Republic Second Faculty of Medicine, Department of Clinical Biochemistry and Pathology, Charles University, Prague, Czech Republic. 3 Second Faculty of Medicine, Department of Clinical Biochemistry and Pathology, Charles University, Prague, Czech Republic.
700    1_
$a Tesner, Pavel $7 xx0242453 $u 4 Second Faculty of Medicine, Department of Biology and Medical Genetics, Charles University, Prague, Czech Republic.
700    1_
$a Cutka, David $u 5 Centre for Medical Genetics, Ceske Budejovice, Czech Republic.
700    1_
$a Stejskal, David $u 6 GENNET Centre for Genetics and Foetal Medicine, Prague, Czech Republic.
700    1_
$a Gregor, Vladimir $u 7 Department of Medical Genetics, Thomayer Hospital, Prague, Czech Republic.
700    1_
$a Zima, Tomas $u 1 First Faculty of Medicine, Department of Medical Biochemistry and Laboratory Diagnostics, Charles University, Prague, Czech Republic.
773    0_
$w MED00002793 $t Journal of medical screening $x 1475-5793 $g Roč. 25, č. 3 (2018), s. 114-118
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29575979 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191126090723 $b ABA008
999    __
$a ok $b bmc $g 1451992 $s 1073882
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 25 $c 3 $d 114-118 $e 20180325 $i 1475-5793 $m Journal of medical screening $n J Med Screen $x MED00002793
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Možnosti archivace